C
0.794
0.09 (13.43%)
| Previous Close | 0.700 |
| Open | 0.780 |
| Volume | 454,166 |
| Avg. Volume (3M) | 104,174 |
| Market Cap | 56,812,608 |
| Price / Book | 1.38 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.330 |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 0.390 |
| Levered Free Cash Flow (TTM) | -1.26 M |
| Return on Assets (TTM) | -20.24% |
| Return on Equity (TTM) | -72.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Citius Oncology, Inc. | Mixed | - |
AIStockmoo Score
-1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | -1.17 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 95.07% |
| % Held by Institutions | 0.89% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock |
| 14 Feb 2025 | Announcement | Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update |
| 14 Feb 2025 | Announcement | Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update |
| 06 Feb 2025 | Announcement | Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services |
| 08 Jan 2025 | Announcement | Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules |
| 07 Jan 2025 | Announcement | Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 |
| 06 Jan 2025 | Announcement | Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |